Genesis Pharmaceuticals Limited

Genesis Pharmaceuticals Limited is a privately held pharmaceutical company based in the United Kingdom, specializing in the wholesale distribution of pharmaceutical goods. (find-and-update.company-information.service.gov.uk) Established on 29 September 1999, the company is headquartered at Scottish Provident House, 3rd Floor, 76 - 80 College Road, Harrow, Middlesex, HA1 1BQ.

The company's primary focus is on the importation and distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Genesis Pharmaceuticals Limited plays a significant role in the UK's pharmaceutical supply chain by supplying wholesalers and hospitals nationwide from a centrally located warehouse.

Genesis Pharmaceuticals Limited operates a centralized distribution model, supplying wholesalers and hospitals across the United Kingdom from its centrally located warehouse. The company's logistics capabilities are designed to ensure timely delivery of pharmaceutical products, leveraging a responsive and high-quality supply chain.

In the United Kingdom's pharmaceutical supply chain, Genesis Pharmaceuticals Limited functions as a primary wholesaler. The company imports finished pharmaceutical formulations from various suppliers, including those in India, and distributes these products to wholesalers and hospitals nationwide.

Genesis Pharmaceuticals Limited's sourcing strategy exhibits a notable concentration on a limited number of suppliers. The company's total import value from India amounts to $1.4 million USD, with 54 shipments covering 29 unique formulations. The top five products imported are Bisacodyl ($1.1 million, 7.3% share) and Lorazepam ($290,000, 7.0% share), indicating a high dependency on these specific products.

This concentration suggests a strategic choice to focus on high-demand products, potentially streamlining operations and ensuring consistent supply. However, it also presents a risk if any of these suppliers face disruptions. The shipment data reveals a stable relationship with Indian suppliers, as evidenced by the consistent import volumes over the years.

Genesis Pharmaceuticals Limited's supply chain resilience is influenced by its reliance on a select group of Indian suppliers. The company's import data indicates a stable relationship with these suppliers, with consistent import volumes over the years.

However, the limited number of suppliers may pose risks in the event of supply chain disruptions. The company's focus on finished pharmaceutical formulations imported from India suggests a reliance on specific shipping routes and regulatory compliance standards. To enhance resilience, it would be prudent for Genesis Pharmaceuticals Limited to diversify its supplier base and establish contingency plans for potential disruptions.

The sourcing pattern of Genesis Pharmaceuticals Limited, characterized by a focus on high-demand products from a limited number of suppliers, positions the company to maintain a streamlined and efficient operation. This strategy allows for better inventory management and potentially stronger relationships with key suppliers.

For Indian exporters, this presents an opportunity to become alternative suppliers by offering competitive pricing, reliable quality, and adherence to regulatory standards. Diversifying the supplier base can help mitigate risks associated with over-reliance on a few suppliers and enhance the company's supply chain resilience.

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) is the primary regulatory body overseeing the importation and distribution of pharmaceutical products. The MHRA ensures that medicines and medical devices meet appropriate standards of safety, quality, and efficacy. (cms.mhra.gov.uk)

Key legislation governing pharmaceutical imports includes the Human Medicines Regulations 2012 (SI 2012/1916), which consolidates and updates previous regulations. This framework outlines the requirements for marketing authorization, importation, and distribution of medicinal products within the UK. (cms.mhra.gov.uk)

Import licensing requirements in the UK are stringent, necessitating that companies like Genesis Pharmaceuticals Limited hold a valid Manufacturer's Authorisation (MIA) issued by the MHRA. This authorization permits the importation and distribution of medicinal products. (cms.mhra.gov.uk)

Good Manufacturing Practice (GMP) certification is also crucial. The MHRA recognizes GMP certificates from the European Union, World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Suppliers from India must ensure their manufacturing facilities are GMP-compliant to meet UK standards. (cms.mhra.gov.uk)

Batch testing and stability requirements are essential to ensure the safety and efficacy of pharmaceutical products. Imported medicines must undergo appropriate testing to confirm they meet UK standards. (cms.mhra.gov.uk)

Labeling must comply with UK regulations, including the use of the English language and adherence to specific information requirements. Serialization mandates may also apply to facilitate traceability and prevent counterfeit products. (cms.mhra.gov.uk)

Between 2024 and 2026, the UK has implemented several regulatory changes affecting pharmaceutical imports. These include updates to the Human Medicines Regulations 2012 to align with European Union standards post-Brexit and enhancements to the MHRA's oversight capabilities. (cms.mhra.gov.uk)

These changes aim to strengthen the safety and quality of imported medicines, impacting companies like Genesis Pharmaceuticals Limited by necessitating compliance with updated standards and procedures.

Genesis Pharmaceuticals Limited's focus on importing Bisacodyl and Lorazepam aligns with market demand in the United Kingdom. Bisacodyl, a stimulant laxative, addresses gastrointestinal issues, while Lorazepam, an anxiolytic, is used for anxiety disorders.

The company's strategy to import these specific therapeutic areas suggests a targeted approach to meet prevalent health concerns, ensuring a steady demand for these products in the UK market.

Genesis Pharmaceuticals Limited's sourcing strategy emphasizes the importation of generic drugs, particularly in the gastrointestinal and central nervous system therapeutic areas. The company's focus on finished pharmaceutical formulations imported from India indicates a preference for suppliers that can provide high-quality products meeting UK regulatory standards.

India's established pharmaceutical manufacturing sector, with its adherence to international GMP standards, positions it as a key supplier for Genesis Pharmaceuticals Limited.

Based on its product mix, Genesis Pharmaceuticals Limited serves the wholesale distribution segment of the United Kingdom market. By supplying wholesalers and hospitals nationwide, the company plays a crucial role in ensuring the availability of essential medicines across the country.

There is a realistic opportunity for new Indian suppliers to engage with Genesis Pharmaceuticals Limited. The company's focus on high-demand products like Bisacodyl and Lorazepam presents avenues for suppliers to offer competitive pricing and reliable quality.

However, potential suppliers must navigate the stringent regulatory requirements of the UK market, including obtaining GMP certification recognized by the MHRA and ensuring compliance with import licensing regulations.

Indian exporters aiming to supply Genesis Pharmaceuticals Limited and the UK market must obtain GMP certification from recognized bodies such as the European Union, WHO, or PIC/S. (cms.mhra.gov.uk)

Additionally, they must comply with the UK's import licensing requirements, including obtaining a valid Manufacturer's Authorisation from the MHRA. (cms.mhra.gov.uk)

To build a relationship with Genesis Pharmaceuticals Limited, Indian exporters should first ensure compliance with UK regulatory standards, including obtaining the necessary certifications and authorizations. (cms.mhra.gov.uk)

Engaging in direct communication with the company's procurement department and participating in relevant tenders can facilitate entry into the UK market. Understanding the specific needs and preferences of Genesis Pharmaceuticals Limited will aid in tailoring product offerings and establishing a successful partnership.